

Examiner-Initiated Interview Summary

Application No.

10/618,298

Applicant(s)

YELLIN ET AL.

Examiner

Phillip Gambel

Art Unit

1644

All Participants:(1) Phillip Gambel.(2) James Haley.**Status of Application:** _____

(3) _____

(4) _____

Date of Interview: 27 March 2007**Time:** _____**Type of Interview:**☐ Telephonic☐ Video Conference☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)Exhibit Shown or Demonstrated: ☐ Yes ☐ No

If Yes, provide a brief description:

Part I.

Rejection(s) discussed:

Claims discussed:

pending

Prior art documents discussed:

Part II.

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

*See Continuation Sheet***Part III.**

☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.

☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

Phillip Gambel
PHILLIP GAMBEL, PH.D.
PRIMARY EXAMINER

*TR 1600**3/27/07*

(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed:

Applicant's election of the species "antibodies (Species A)" and the species "vasculitis (Species H)" in the Reply to Restriction Requirement, filed 1/8/07, was acknowledged.

Upon a review of the instant claims as they read on the elected species, the following was noted.

This application contains claims directed to the following patentably distinct species of the claimed invention: wherein the "antibody / antibodies" is / are:

- A) CD40-specific antibody / antibodies or.
- B) CD40L-specific antibody / antibodies.

During a telephone conversation with James Haley on 03/27/2007, a provisional election was made with traverse to prosecute the species of CD40L-specific antibodies in addition to the species indicated above.